CMS is allowing the plans to pursue what are known as “indication-based formulary designs,” which are already used by private insurers. “By allowing Medicare’s prescription drug plans to cover the best drug for each patient condition, plans will have more negotiating power with drug companies, which will results in lower prices for Medicare beneficiaries,” CMS administrator Seema Verma said